New Oral Drugs for Pulmonary Arterial Hypertension: Macitentan, Riociguat, and Treprostinil

Advances in Pulmonary Hypertension

Caccamo, M¹ 

关键词: Cardiology;    Pulmonology;    Rheumatology;    Pediatrics;    Lifestyle Issues;    WHO Group 1- Pulmonary Arterial Hypertension;    WHO Group 4;    PH Medications;    Surgical Interventions;    Anatomy;    Physiology/Pathophysiology;    symptoms;    Research;    Exercise;    nutrition;    Cardiopulmonary rehabilitation;    Associated Diseases;    HIV Infection;    Chronic thromboembolic pulmonary hypertension;    hematologic disorder;    Oral therapy;    IV therapy;    Subcutaneous therapy;    Inhaled therapy;    Prostacyclin;    Endothelin Receptor Antagonists;    pharmacokinetics;    nitric oxide;    Anticoagulation;    Non-invasive estimate of PVR;    Pulmonary vascular resistance;    exercise hemodynamic testing;    6-Minute Walk Test;    thromboendarterectomy;    endothelial dysfunction;    Endothelin;    tricuspid regurgitation;    syncope;    hypoxia;    Functional Class;    patient-reported outcomes;    Drug development;    clinical trial;    clinical trial endpoints;    biomarkers;    REVEAL;    Side Effects;    pre-clinical research;    Classification;    Epidemiology;   

DOI  :  

学科分类：医学（综合）

来源: Pulmonary Hypertension Association

 

【 授权许可】

All Rights reserved